Tag: pfizer

Pfizer Says Lyme Vaccine Missed Trial Target, Will Still Seek Approval

Pfizer and its partner Valneva said on March 23 that their experimental Lyme disease vaccine did not meet the target in a clinical trial, but that the results were strong enough that the firms will seek regulatory approval for the shot.

The vaccine, known as LB6V, was about 75 percent efficacious in reducing confirmed Lyme in recipients compared with placebo recipients, the companies said. The efficacy was measured one day after the fourth vaccine dose, and was similar to the 73 percent efficacy observed 28 days after the fourth shot.

The drugmakers said that because there were fewer Lyme cases than expected during the trial, dubbed VALOR, the predetermined statistical target was not met. However, because the efficacy was “clinically meaningful,” the companies expressed confidence in the shot and said they would be filing for approval.

“The efficacy shown in the VALOR study of more than 70 percent is highly encouraging and creates confidence in the vaccine’s potential to protect against this disease that can be debilitating,” Annaliesa Anderson, Pfizer’s chief vaccines officer, said in a statement.

Valneva CEO Thomas Lingelbach said: “[The results] bring us a step closer to our goal of delivering a much-needed vaccine.

“We are grateful to our partner Pfizer for their strong commitment which we both share in developing this vaccine as quickly as possible.”

Keep reading

Former Australian Member of Parliament Says Pfizer and AstraZeneca Paid Lobbyists to Direct Australia’s Leaders to Push Vaccine Mandates

A former Australian member of Parliament came out and said Pfizer and AstraZeneca are paying lobbyists to direct Australia’s leaders to push vaccine mandates.Clive Palmer, leader of the United Australia Party claimed ousted New South Wales Premier Gladys Berejiklian was told she wouldn’t be charged in a corruption probe if she imposed a vaccine mandate.Palmer made these statements a couple weeks ago but it has garnered a lot of attention this weekend after Berejiklian resigned in disgrace following a corruption probe.Two weeks ago, Palmer said Pfizer and AstraZeneca were paying lobbyists tens of millions of dollars to direct Australia’s liberal leaders to push the double jab.According to Palmer, Berejiklian, who was under a corruption probe by the ICAC at the time, was told if she imposed strict lockdowns and vaccine mandates, she wouldn’t be charged.Shortly before Berejiklian resigned, she told Sydney residents that if they don’t take the Covid jab, they face total social isolation indefinitely after the stay-at-home order ends in December.Berejiklian made history for overseeing one of the most fascistic regimes in modern history like nothing we have witnessed in the Western world.It appears she was bowing to Big Pharma lobbyists and special interest groups once again proving Covid mandates have NOTHING to do with science or saving lives.Clive Palmer told reporters of Berejiklian: “The only way she gets out of the inquiry is if she pushes the double jab.”A lefty reporter pushed back on Clive Palmer: “You think the premier of New South Wales is trying to destroy businesses?”“I do,” Palmer replied. “She’s being directed by lobbyists in Sydney, who is being paid by AstraZeneca and by Pfizer tens of millions of dollars to get these policies through, to make sure the vaccines get pushed…that’s my personal knowledge and I’m happy to make a statement here, to police, to anyone.”

Keep reading

Bill Gates, Pfizer CEO Albert Bourla Ordered to Testify in Dutch COVID Vaccine Injury Lawsuit

Bill Gates and Pfizer CEO Albert Bourla will have to appear in person in the Netherlands to testify at a hearing in a COVID-19 vaccine injury lawsuit, a Dutch court ruled late last month.

The court order relates to a lawsuit filed in 2023 by seven people injured by COVID-19 vaccines. One of the victims has since died.

The lawsuit centers around the question “of whether the COVID-19 injections are a bioweapon,” Dutch newspaper De Andere Krant reported. In addition to Gates and Bourla, the suit names 15 other defendants, including former Dutch prime minister and current NATO Secretary General Mark Rutte, the Dutch state, and several Dutch public health officials and journalists.

De Andere Krant said last month’s ruling “is a significant setback for the defendants, who are accused of misleading victims about the ‘safety and effectiveness’ of the vaccines.” However, it “remains to be seen” whether the defendants will comply with the court’s order and appear at next year’s hearing.

The defendants may face additional legal challenges in Dutch courts in the new year. A second lawsuit, filed in March by three COVID-19 vaccine injury victims in the Netherlands, presents a similar set of allegations and names the same defendants.

At a press conference last week, Dutch attorney Peter Stassen, who represents the vaccine-injured plaintiffs in both cases, earlier this month petitioned the courts in both cases to hear in-person testimony by five expert witnesses regarding the safety and efficacy of the mRNA COVID-19 vaccines.

According to Stassen, oral hearings will be held in both cases next year, but hearing dates have not yet been scheduled. Stassen seeks to consolidate the cases.

Keep reading

Teen Who Died 5 Days After Pfizer Vaccine Among 10 Deaths FDA Cited In Leaked Memo

Last week, a leaked FDA memo acknowledged that at least ten children died “after and because of” the COVID-19 vaccine in the U.S.

None of those children had been identified — until now.

One of them is now understood to be Ernesto Ramirez Jr., a 16-year-old from Texas who collapsed and died five days after receiving the Pfizer COVID-19 shot.

“Junior,” as he is known, is among the cases at the center of the U.S. Food and Drug Administration’s (FDA) internal investigation into pediatric deaths following COVID-19 vaccination.

For his father, Ernest Ramirez, the past four years have been consumed by grief, tireless campaigning and what he describes as a “living hell.”

Now, for the first time, he believes the FDA has acknowledged what he has always known — the vaccine took his child.

“That’s the poison that killed my son,” he told me.

A father fights for his son

Junior was healthy, athletic and inseparable from his dad. Ernest raised him alone.

“We were always together, we were never apart,” he said. “Like I’ve always said, he was my best friend … We were buddies.”

Five days after the Pfizer shot, Junior went to the park with a neighbor to play basketball.

“They started running and he just collapsed,” Ernest said.

Paramedics rushed him to the hospital, but attempts to revive him failed. Ernest still remembers the bluntness of the staff.

“Yeah, you can go home now, your son’s dead,” is how he recalls the doctor’s tone.

He could not return to the empty house.

At first, he had no idea the vaccine could have been involved. It wasn’t until cardiologist Dr. Peter McCullough reviewed the records that Ernest heard the words that changed everything.

Keep reading

Pfizer buries data showing mRNA flu vaccine bombed in trial with elderly, not much better under 65

wo years ago, Pfizer anticipated that sales of its rebound-prone COVID-19 oral antiviral Paxlovid and fully approved mRNA COVID vaccine Comirnaty would plummet, but good news appeared on the horizon: The drugmaker’s mRNA flu vaccine did well in phase 3 trials in ages 18-64, and Pfizer expected to release results from the 65-and-up cohort “later this year.”

The results are finally in: Compared to a standard flu shot, the mRNA vaccine was associated with six times as many adverse events as infections prevented in adults under 65, and it outright failed in elderly people, associated with more deaths and both minor and serious injuries, from injection-site swelling to kidney problems.

The company buried the long-delayed elderly results on the government’s clinical trials website this spring, more than a year late and without announcing them to the public or investors, and gave an optimistic take on the under-65 results in the New England Journal of Medicine last week, while admitting the mRNA shot was “associated with more reactogenicity events.”

Australian and American drug industry journalists dug into the two arms of the trial, predicting mRNA jabs for flu would face an uphill climb with Trump administration regulators, who have already canceled nearly $500 million in federal projects and contracts that went toward mRNA vaccine development.

Pfizer used the same testing structure for mRNA flu shots as for its COVID shots and still found only an absolute difference of 0.32% for under-65s, requiring vaccination by 300 people to “prevent a single mild, self-limiting illness,” physician-turned-investigative journalist Maryanne Demasi wrote in an X thread summarizing her deep-dive review.

“Put simply, it’s a manufacturer-funded trial, written largely by Pfizer employees & finds its best efficacy in the endpoint that requires all samples to be shipped to a Pfizer-run central lab for adjudication,” Demasi said.

Keep reading

We know exactly how and why the DNA is in the Moderna and Pfizer vials

This past week has been epic for me. Not only did I have the extreme pleasure of volunteering alongside Kevin McKernan and Charles Rixey at Medicinal Genomics, but we have pretty much confirmed how the DNA is in the Moderna and Pfizer COVID shot vials.

Ages ago, when I was presenting the original findings that there was DNA in these vials, I was sleuthing how this happened by looking into the N1-methylpseudouridine modified RNA synthesis pathway as part of Process 2 manufacturing. Process 2 involved using a plasmid/E. coli system, don’t forget. And also don’t forget that this methodology was bait ‘n’ switched and was not safety tested.

N1-methylpseudouridine has a higher melting temperature than Uridine.1 (Higher thermal energy or specific enzymatic activity is required to disrupt base pairing.) What this means in terms of it binding a cognate base is that it will require a very high temperature to rip them apart. Either that, or it will require a specific enzyme. Two examples of such specific enzymes are RNase-H (in us) and RNase-XT (on bench). It is well-known in nerdy science circles that DNase1 – the enzyme the COVID shot manufacturers used to chop up the DNA for endpoint synthesis cleaning – does not work on DNA:RNA hybrids.

Keep reading

Smoke, Mirrors, and the Pfizer Deal

Iam a mother. I have never been vaccinated myself. I believe deeply in informed consent. And I want to say clearly that I am hopeful about Bobby’s leadership at HHS. I want to believe that he can bring real transparency and accountability to a government that has too often cozied up to the corporations it is supposed to regulate.

But when I read the headlines about Trump’s “landmark” deal with Pfizer, I don’t feel hopeful. I feel misled.

We are told that Pfizer has committed $70 billion to research, development, and production here in the United States. That sounds impressive, like a historic victory for the American people. But the truth is, Pfizer already spends billions every year on research and development. That is simply the business they are in. Without that constant pipeline, they do not survive.

So what is really new here? Nothing at all. It is the same budget they were already going to spend, repackaged and sold as a bold new commitment. The difference now is that Pfizer gets something in return: tariff relief, political cover, and a government-backed direct-to-consumer program called TrumpRx.

That is what makes this deal so frustrating. Pfizer is not changing its behavior. They are not suddenly sacrificing profits or doing more for patients. They are being rewarded for business as usual, only now with added advantages that strengthen their market position even more. And we are being asked to celebrate it as if it is some great victory for ordinary families.

Every producer wants to cut out the middleman. I know this from my own life. As a meat producer, I do not want to pay one. As a vegetable producer, I do not want to pay one. As a content creator, I do not want to pay one. Nobody does. And now Pfizer, of all companies, is getting the official blessing of the US government to do exactly that.

This is the same Pfizer that misled the public during Covid. That is not a rumor, it is documented. Whistleblowers from trial sites described falsified records, patients who were not properly followed up after adverse events, and unqualified staff handling sensitive data. State attorneys general have accused Pfizer of downplaying serious risks, including heart inflammation in young men and pregnancy complications in women. 

Kansas has even claimed the company hid internal studies that showed risks while telling the public something different. And the most central promise of all, that the vaccines would stop transmission, simply was not true, even though the marketing never caught up to that reality.

Keep reading

Pfizer Left COVID-19 Vaccine Data Out Of Submissions To FDA, Documents Show

Data on how parts of a Pfizer-BioNTech COVID-19 vaccine spread in the bodies of mice were withheld from regulatory submissions to the U.S. Food and Drug Administration, according to a new comparison of those submissions and similar documents sent to Japanese regulators.

Byram Bridle, who has a PhD in immunology and is an associate professor of immunology and virology at the University of Guelph in Canada, authored the comparison. It was dated Aug. 13 and released on Oct. 4 by Dr. Robert Malone, a vaccine adviser to the U.S. government.

“The findings of this report raise serious questions about the integrity of the health regulatory process during the declared COVID-19 pandemic,” Bridle said in his conclusions.

During a September meeting, under questioning by Malone, a Pfizer representative said that its studies of the spread of vaccine elements, known as biodistribution, were done in consultation with the FDA.

“Pfizer does not have a further comment other than we did our work in close consultation with the FDA on all our of biodistribution studies that were approved for our licensed product,” the representative said.

As Zachary Stieber details below, Malone told The Epoch Times that the images in the submissions appear to have been manipulated “to hide the fact that the biodistribution was much broader than the initial narrative that was promoted, which is that it stays at the site of injection and draining lymph nodes.”

He added: “That was clearly a lie, and it was a lie that we now know was supported by editing data that were presented to the FDA. And, according to what the Pfizer representative stated, that editing of data was done in cooperation and consultation between Pfizer and the FDA. That is completely unacceptable.”

Pfizer, BioNTech, and the FDA did not respond to requests for comment.

Keep reading

TrumpRx Is Obamacare in Trump’s Handwriting

This week, President Donald Trump announced the next in a long line of vanity projects: TrumpRX, a forthcoming, federally branded website where Pfizer sells steeply discounted drugs in exchange for a three-year exemption from his proposed 100 percent tariffs on imported pharmaceuticals. Imagine a strip mall furniture store with a permanent, flashy 70-percent-off sale, masking the fact that prices were inflated in the first place. TrumpRx, slated to launch in early 2026, is no different—a government-run platform that promises savings while hiding costs.

But this isn’t just another Trump-branded vanity project like the ill-fated Trump Steaks or Trump University. It’s a wild pivot in right-leaning political thought on health care, and it’s a gut punch for those who see where this road leads.

Flash back to 2016: Trump hammering the Affordable Care Act, calling it a “disaster” and suggesting that the government’s only role should be to ensure these companies have “plenty of money.” He was channeling what economists had long warned: Government-run health care distorts markets, creates perverse incentives, and collapses under its own weight. Now, the president is embracing the very heavy-handed tactics he once trashed.

Keep reading

Pfizer Strikes $70 Billion Deal with U.S. to Expand Its mRNA Empire, Lower Drug Prices

Today, Pfizer announced a “landmark agreement” with the Trump Administration. The press release promised lower drug costs and a revival of U.S. manufacturing. President Donald Trump touted that Pfizer would cut Medicaid drug prices for low-income Americans and sell new medicines at a “most-favored-nation” price — but only in exchange for tariff relief.

In reality, it appears to be a multi-billion dollar effort to entrench Pfizer’s failed gene-transfer platforms for decades to come.

The deal secures a $70 billion commitment to U.S. R&D — a down payment on Pfizer’s next wave of gene-based products:

  • Cancer “vaccines”
  • Obesity injections
  • Expanded vaccine portfolio (flu, RSV, bird flu, more)
  • Chronic disease biologics in inflammation & immunology

Pfizer itself spelled it out:

“With this agreement in place, Pfizer can fully focus on delivering the next generation of cures… in areas like oncology, obesity, vaccines, and inflammation and immunology.”

This comes after Pfizer’s COVID-19 gene-based products have already been linked to catastrophic injuries, deaths, and disabilities worldwide. Instead of scrutiny, the company is rewarded with protection and growth.

Keep reading